[go: up one dir, main page]

IN2014DN07799A - - Google Patents

Info

Publication number
IN2014DN07799A
IN2014DN07799A IN7799DEN2014A IN2014DN07799A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A IN 7799DEN2014 A IN7799DEN2014 A IN 7799DEN2014A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A
Authority
IN
India
Prior art keywords
antibody
present disclosure
rob04
angiogenesis
pharmaceutical composition
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshitaka Isumi
Toshiyuki Sato
Jun Hasegawa
Tatsuya Inoue
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2012103929A external-priority patent/JP2013230115A/ja
Priority claimed from JP2013011042A external-priority patent/JP2014141434A/ja
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IN2014DN07799A publication Critical patent/IN2014DN07799A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
IN7799DEN2014 2012-04-27 2013-04-26 IN2014DN07799A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012103929A JP2013230115A (ja) 2012-04-27 2012-04-27 抗ｒｏｂｏ４抗体
JP2013011042A JP2014141434A (ja) 2013-01-24 2013-01-24 抗ｒｏｂｏ４抗体
PCT/IB2013/053312 WO2013160879A1 (fr) 2012-04-27 2013-04-26 Anticorps anti-robo4

Publications (1)

Publication Number Publication Date
IN2014DN07799A true IN2014DN07799A (fr) 2015-05-15

Family

ID=48670623

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7799DEN2014 IN2014DN07799A (fr) 2012-04-27 2013-04-26

Country Status (22)

Country Link
US (2) US9683040B2 (fr)
EP (1) EP2841457B1 (fr)
JP (2) JP5897205B2 (fr)
KR (2) KR101950898B1 (fr)
CN (1) CN104768973B (fr)
AU (1) AU2013254313B2 (fr)
BR (1) BR112014026649A2 (fr)
CA (1) CA2868074A1 (fr)
CO (1) CO7111295A2 (fr)
DK (1) DK2841457T3 (fr)
ES (1) ES2733434T3 (fr)
IN (1) IN2014DN07799A (fr)
MX (1) MX356749B (fr)
MY (1) MY166821A (fr)
NZ (1) NZ629291A (fr)
PH (1) PH12014502382A1 (fr)
PL (1) PL2841457T3 (fr)
RU (1) RU2682451C2 (fr)
SG (1) SG11201405718QA (fr)
TW (1) TWI606065B (fr)
WO (1) WO2013160879A1 (fr)
ZA (1) ZA201406235B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405718QA (en) * 2012-04-27 2014-10-30 Daiichi Sankyo Co Ltd Anti-robo4-antibody
EP4349997A3 (fr) 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anticorps anti-garp
JPWO2018070390A1 (ja) * 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
KR20210070643A (ko) 2019-12-05 2021-06-15 김명배 자체 발전 웨어러블 다리
WO2023156437A1 (fr) 2022-02-16 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps monoclonaux humains anti-robo4 et leurs utilisations pour traiter le cancer
WO2025045139A1 (fr) * 2023-08-31 2025-03-06 舒泰神（北京）生物制药股份有限公司 Anticorps reconnaissant de manière spécifique robo2 et son utilisation
CN117384290B (zh) * 2023-12-11 2024-04-09 苏州因特药物研发有限公司 人源robo1结合分子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (fr) 1993-12-03 1996-09-18 Medical Research Council Proteines et peptides de liaison recombines
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
EP1790728B1 (fr) * 2000-11-06 2010-09-08 Cancer Research Technology Limited Imagerie, diagnostic et traitement de maladie
JP4583638B2 (ja) 2001-03-15 2010-11-17 独立行政法人科学技術振興機構 アセチルリジン認識モノクローナル抗体及びその製造方法
AU2003247828B2 (en) 2002-06-27 2010-05-20 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
CA2506724C (fr) 2002-11-20 2013-03-12 Cancer Research Technology Limited Anticorps, polypeptides et leurs usages
BRPI0406678A (pt) 2003-01-07 2005-12-20 Symphogen As Método para produzir proteìnas policlonais recombinantes
BRPI0720038A2 (pt) 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
NZ578701A (en) 2007-02-09 2012-02-24 Genentech Inc Anti-robo4 antibodies and uses therefor
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
SG11201405718QA (en) * 2012-04-27 2014-10-30 Daiichi Sankyo Co Ltd Anti-robo4-antibody

Also Published As

Publication number Publication date
JP5897205B2 (ja) 2016-03-30
CA2868074A1 (fr) 2013-10-31
AU2013254313A1 (en) 2014-09-18
EP2841457B1 (fr) 2019-04-24
KR20190020838A (ko) 2019-03-04
TW201348257A (zh) 2013-12-01
US20160108120A1 (en) 2016-04-21
ZA201406235B (en) 2016-07-27
PH12014502382B1 (en) 2015-01-12
CN104768973A (zh) 2015-07-08
JP2015515490A (ja) 2015-05-28
AU2013254313B2 (en) 2017-03-30
HK1207093A1 (en) 2016-01-22
MX2014012351A (es) 2015-01-12
EP2841457A1 (fr) 2015-03-04
RU2682451C2 (ru) 2019-03-19
ES2733434T3 (es) 2019-11-29
NZ629291A (en) 2016-09-30
WO2013160879A1 (fr) 2013-10-31
US9562096B2 (en) 2017-02-07
BR112014026649A2 (pt) 2017-07-18
KR20150008074A (ko) 2015-01-21
CN104768973B (zh) 2019-01-22
US20150098945A1 (en) 2015-04-09
CO7111295A2 (es) 2014-11-10
MX356749B (es) 2018-06-12
PL2841457T3 (pl) 2019-09-30
SG11201405718QA (en) 2014-10-30
DK2841457T3 (da) 2019-07-22
KR101950898B1 (ko) 2019-02-22
MY166821A (en) 2018-07-23
US9683040B2 (en) 2017-06-20
TWI606065B (zh) 2017-11-21
RU2014147616A (ru) 2016-06-20
PH12014502382A1 (en) 2015-01-12
JP6267733B2 (ja) 2018-01-24
JP2016175893A (ja) 2016-10-06

Similar Documents

Publication Publication Date Title
IN2014DN07799A (fr)
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
EP2761554A4 (fr) Paiements sociaux de proximité
EP2786664A4 (fr) Procédé de préparation de pulpe pour cigarette électronique et narguilé classique
EP2863910A4 (fr) Compositions et procédés pour réguler l'homéostasie du glucose et l'action de l'insuline
IL233796A0 (en) Correlating brain signal to intentional and unintentionall changes in brain state
AU341611S (en) Dual function wine system
EP2917235A4 (fr) Compositions d'anticorps et procédés d'immunodosage pour détecter des isoformes de l'hormone antimüllérienne
EP3030244A4 (fr) Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo
PL2935595T3 (pl) Sposób i urządzenie do wytwarzania biogazu z biomasy zawierającej lignocelulozę
IL236197A0 (en) In vitro method for the diagnosis and surveillance of cancer
EP2832694A4 (fr) Cristal germe de zéolite ddr, procédé pour le produire, et procédé pour produire un film de zéolite ddr
MX2015010429A (es) Cetuximab con glicosilación modificada y sus usos.
WO2014209905A3 (fr) Méthodes et compositions destinées à détecter et à diagnostiquer des maladies et des affections
MX2014004211A (es) Composiciones de recubrimiento para moldes y machos de fundicion inorganicos que comprenden esteres de acido formico y uso de los mismos.
EP2771688A4 (fr) Anticorps anti-psa libres en tant que produits de diagnostic, de pronostic et thérapeutiques pour le cancer de la prostate
EP3031914A4 (fr) AMADORIASE MODIFIÉE ET SON PROCÉDÉ DE PRODUCTION, AGENT PERMETTANT D'AMÉLIORER LA RÉSISTANCE AUX TENSIOACTIFS DE L'AMADORIASE ET COMPOSITION PERMETTANT DE MESURER L'HbA1c À L'AIDE DE CELLE-CI
IN2014MN02114A (fr)
AU343147S (en) Easel
EP3009008A4 (fr) Céréale contenant hericium erinaceum et procédé pour la produire
EP2714923A4 (fr) Méthodes et compositions pour la détection de toxines de clostridium difficile fonctionnelles
EP3049142A4 (fr) Extension pour cathéter et ses procédés de production et d'utilisation
EP3025282A4 (fr) Système et procédé d'extraction d'attributs de changement matériel à partir de signaux de données conservés et analysés au fil du temps afin de prévoir des changements futurs dans des prédicteurs traditionnels
EP2918678A4 (fr) Anticorps anti-adam28 pour traiter le cancer
EP2687222A4 (fr) Agent de promotion de production de bléomycine hydrolase